Cart
sales@molnova.com
PI3Kδ-IN-7n
CAS No. 2088525-31-7
PI3Kδ-IN-7n( —— )
Catalog No. M13260 CAS No. 2088525-31-7
PI3Kδ-IN-7n is a highly potent and selective PI3Kδ inhibitor with IC50 of 0.9 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 150 | In Stock |
|
| 10MG | 226 | In Stock |
|
| 25MG | 372 | In Stock |
|
| 50MG | 498 | In Stock |
|
| 100MG | 681 | In Stock |
|
| 200MG | 917 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePI3Kδ-IN-7n
-
NoteResearch use only, not for human use.
-
Brief DescriptionPI3Kδ-IN-7n is a highly potent and selective PI3Kδ inhibitor with IC50 of 0.9 nM.
-
DescriptionPI3Kδ-IN-7n is a highly potent and selective PI3Kδ inhibitor with IC50 of 0.9 nM, displays high selectivity (>1,500-fold) over PI3Kα, PI3Kβ, PI3Kγ (IC50>1.5 uM); shows reasonable pharmacokinetics with good bioavailability and moderate in vivo half-life; one of the most selective PI3Kδ inhibitors published to date.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayPI3K/Akt/mTOR signaling
-
TargetPI3K
-
RecptorPI3K
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2088525-31-7
-
Formula Weight429.459
-
Molecular FormulaC23H20FN7O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name4-(3-amino-6-(1-methyl-5-(1-phenylcyclopropyl)-1H-1,2,4-triazol-3-yl)pyrazin-2-yl)-2-fluorobenzamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Terstiege I, et al. Bioorg Med Chem Lett. 2017 Feb 1;27(3):679-687.
molnova catalog
related products
-
TGR-1202 R-enantiome...
TGR-1202 R-enantiomer is is the less active enantiomer of TGR-1202 (Umbralisib), TGR-1202 is a potent, selective, orally available PI3Kδ inhibitor with IC50 of 22 nM.
-
SAR405
SAR405 is a highly potent and selective PI3K class III isoform Vps34 inhibitor with IC50 of 1.2 nM.
-
PARP,PI3K-IN-1
PARP/PI3K-IN-1 is a novel dual poly (ADP-ribose) polymerase (PARP) and phosphatidylinositol 3-kinase (PI3K) dual inhibitor with anticancer, antitumour and antiproliferative activities for the study of breast, pancreatic and lung cancers.
